New Orleans – Novartis announced this morning that their novel pan-HDAC inhibitor, panobinostat (LBH589) in combination with bortezomib (Velcade) and dexamethasone significantly prolonged progression-free survival (PFS) of patients with Multiple Myeloma in the phase III PANORAMA-1 trial.

 Panobinostat may change Multiple Myeloma Competitive Landscape

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $129 a month (THIS SUBSCRIPTION AUTOMATICALLY BILLS YOUR CREDIT CARD EACH MONTH UNTIL YOU CANCEL) or $327 for 3 months access (does not auto renew), $997 for 12 months access (does not auto renew). Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if a communications professional our Guidance to PR Professionals contained within it.